Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population
Modern Rheumatology · 04.07.2023 · 33 (4) · 680-689
DOI: 10.1093/mr/roac103 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, online erschienen am 03.09.2022. Verfasst von Yoshiya Tanaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The aim of this article is to evaluate the efficacy and safety of subcutaneously administered methotrexate (MTX) for Japanese patients with active rheumatoid arthritis.
Methods
MTX-naïve patients were randomized in a 1:1 ratio to receive a 12-week administration of either 7.5 mg MTX subcutaneously (MJK101, a prefilled syringe for subcutaneous injection) or 8 mg MTX orally in Part 1 of the trial. The primary end point was a 20% improvement in the American College of Rheumatology criteria (ACR20) at Week 12. In the second part, all enrolled patients received MJK101 weekly for 52 weeks with doses starting from 7.5 to 15 mg with 2.5 mg increments with the option of self-administration of MJK101.
Results
The efficacy of MJK101 was comparable to oral MTX following 12 weeks of treatment at the starting doses. A numerically higher ACR20 response rate and fewer adverse events in particular gastrointestinal adverse events were observed. During long-term subcutaneous treatment, MJK101 was well tolerated across all tested doses. Patients clinically improved upon dose escalation.
Conclusions
Subcutaneously applied MTX (MJK101) was efficient and well tolerated over a long-term treatment period in the Japanese population with doses up to 15 mg/week. Subcutaneous administration of MTX is a beneficial option for Japanese patients with rheumatoid arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Matsubara Mayflower Hospital, Kato, Japan.
- Department of Rheumatology, Sanuki Municipal Hospital, Sanuki, Japan.
- Katayama Orthopedic Rheumatism Clinic, Asahikawa, Japan.
- Department of Rheumatology, Daido Clinic, Nagoya, Japan.
- Hiroshima Rheumatology Clinic, Hiroshima, Japan.
ORCID-Profile: Yoshiya Tanaka
Zitieren
APA
Tanaka, Y., Okuda, K., Takeuchi, Y., Katayama, K., Haji, Y., Yamanishi, Y., Tribanek, M., Guimbal-Schmolck, C., & Takeuchi, T. (2023). Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Modern Rheumatology, 33(4), 680-689. https://doi.org/10.1093/mr/roac103
Vancouver
Tanaka Y, Okuda K, Takeuchi Y, Katayama K, Haji Y, Yamanishi Y, et al. Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population. Modern Rheumatology. 2023;33(4):680-689. doi:10.1093/mr/roac103
BibTeX
@article{Tanaka2023,
author = {Tanaka, Yoshiya and Okuda, Kosuke and Takeuchi, Yohei and Katayama, Kou and Haji, Yoichiro and Yamanishi, Yuji and Tribanek, Michael and Guimbal-Schmolck, Cecile and Takeuchi, Tsutomu},
title = {Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population},
journal = {Modern Rheumatology},
year = {2023},
volume = {33},
number = {4},
pages = {680--689},
doi = {10.1093/mr/roac103}
}
EUVIMED